Searched for
KOTAK SECURITIES PHARMA
Why did stock market rally today? Sensex jumps 736 points, Nifty closes above 23,850. 5 key factors behind bull runIndian equities surged nearly 1% as bulls charged through Dalal Street, driven by an Iran-US peace framework and sliding oil prices. The Se...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmerIndian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their ef...
- Why market rallied today? Sensex jumps 1,074 points, Nifty closes above 24,000. 5 factors behind surgeIndian stock markets surged on Monday, with Sensex and Nifty rallying over 1% each, driven by rising hopes of a US-Iran peace deal and fall...
- Market wrap: Sensex rises 232 points, Nifty closes above 23,700 as rupee recovers from lifetime lowsIndian markets ended the week higher after recovering intraday volatility, with Sensex and Nifty posting modest gains amid hopes of easing ...
- Ahead of Market: 10 things that will decide stock market action on WednesdayDomestic equities closed marginally lower due to weakness in financial and consumer shares, despite gains in IT stocks. Analysts suggest th...
- Sensex drops 114 points, Nifty below 23,650 as rupee hits fresh lifetime low; broader markets outperformIndian markets ended lower on Tuesday as Sensex and Nifty erased early gains amid rupee weakness, even as volatility cooled. IT stocks outp...
- Sensex falls 114 points, Nifty closes below 24,350; broader markets outperformIndian stock markets surged on Thursday, with Sensex and Nifty extending gains for a second day. This rise was fueled by optimism over a po...
- Bullish on power, energy, and BFSI; cautious on IT amid weak earnings: Devarsh VakilHDFC Securities sees opportunity in India's recovering equity markets. The firm favors power and energy sectors, citing infrastructure grow...
- Earnings vs signals: Q4 results may matter more than they lookThe March quarter earnings season arrives at an inflection point, with stable numbers masking underlying economic shifts. Escalation of the...
- Ceasefire calm or chaos? 50 stocks that brokerages expect to rally after Iran truceA two-week US-Iran ceasefire has sparked a relief rally in Indian equities, though its sustainability is questioned as oil prices rebound. ...
- Iran war, earnings hit and more: Brokerages identify nearly 80 stocks from a battered Indian market for FY27Brokerages see the recent market correction driven by geopolitical tensions and rising oil prices as a buying opportunity, identifying near...
- Bankruptcy court admits BSE-listed Supha Pharmachem under Insolvency Resolution ProcessThe Mumbai bench of the National Company Law Tribunal has admitted Supha Pharmachem into the Corporate Insolvency Resolution Process (CIRP)...
- Block Deal: Hema CIPEF likely to sell around 1% stake in Mankind PharmaCapital Group held a 2.22% stake in the company as on March 31, 2024. In December last year, Capital Group divested a 3.14% stake in Mankin...
- Investors irked by lack of disclosures at Sun PharmaThe lack of disclosures around non-related party transactions to the tune of Rs 2,200 crore has become a sore spot for investors, who are q...
- Buy Natco Pharma Ltd. with a target of Rs 750 – Kotak Securities LimitedBuy Natco Pharma Ltd. with a target of Rs 750. The stock, Kotak Securities believes will continue to trade at higher multiples given the ev...
- Natco Pharma expected to touch 170-172: Kotak SecuritiesShrikant Chouhan, senior vice president, Technical Research, Kotak Securities, in a chat with ET Now talks about Natco Pharma.
- Pharma space is very defensive: Kotak SecuritiesShrikant Chouhan, SVP, Technical Research, Kotak Securities, in a chat with ET Now talks the pharma space.
Load More
